Engineered immune cells take aim at autoimmune diseases

NCT ID NCT05459870

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether specially engineered immune cells, called CAR-T cells, can safely treat autoimmune diseases. The cells are designed to target and suppress B cells, which play a key role in many autoimmune conditions. The trial involves 30 adults and focuses on safety and how well the cells work.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

4SCAR T cells

What this could lead to

If successful, this approach could offer a new way to control autoimmune diseases by targeting the immune cells that drive them.

What could go wrong

This is an early-phase trial with only 30 participants, so results may not apply broadly. CAR-T therapy carries risks like severe immune reactions and infections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shenzhen Geno-immune Medical Institute

    RECRUITING

    Shenzhen, Guangdong, 518000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••